Edition:
United Kingdom

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

79.55USD
7:56pm GMT
Change (% chg)

$-0.26 (-0.33%)
Prev Close
$79.81
Open
$79.63
Day's High
$80.12
Day's Low
$79.08
Volume
1,018,010
Avg. Vol
4,355,100
52-wk High
$80.18
52-wk Low
$52.83

Select another date:

Sat, Feb 16 2019

Photo

Merck, Pfizer drug combo extends kidney cancer survival: study

A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday.

Merck, Pfizer drug combo extends kidney cancer survival -study

Feb 16 A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday.

Merck to further study Keytruda in prostate cancer after early success

Merck & Co Inc said on Thursday it was launching three late-stage studies for its cancer immunotherapy Keytruda as a combination treatment for prostate cancer after the drug showed anti-tumor activity in an early-stage trial.

REFILE-Merck to further study Keytruda in prostate cancer after early success

Feb 14 Merck & Co Inc said on Thursday it was launching three late-stage studies for its cancer immunotherapy Keytruda as a combination treatment for prostate cancer after the drug showed anti-tumor activity in an early-stage trial.

Merck, Pfizer combo treatment boosts kidney cancer survival

NEW YORK Drugmaker Merck & Co Inc said on Monday that the combination of its cancer immunotherapy Keytruda with Pfizer Inc's Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with chemotherapy drug Sutent.

REFILE-Merck, Pfizer combo treatment boosts kidney cancer survival

NEW YORK, Feb 11 Drugmaker Merck & Co Inc said on Monday that the combination of its cancer immunotherapy Keytruda with Pfizer Inc's Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with chemotherapy drug Sutent.

Merck CEO Frazier to testify at Senate drug pricing hearing

NEW YORK/WASHINGTON U.S. drugmaker Merck & Co Inc said on Tuesday that its Chief Executive Ken Frazier plans to testify at a Senate hearing later this month examining rising prescription drug prices.

UPDATE 2-Merck CEO Frazier to testify at Senate drug pricing hearing

NEW YORK/WASHINGTON, Feb 5 U.S. drugmaker Merck & Co Inc said on Tuesday that its Chief Executive Ken Frazier plans to testify at a Senate hearing later this month examining rising prescription drug prices.

WHO and vaccine group back 'critical' cervical cancer shots

(This Feb. 4 story corrects seventh para to say Merck's Gardasil vaccine targets nine (not four) strains of HPV)

Merck CEO Frazier plans to testify at Senate drug pricing hearing

NEW YORK, Feb 5 U.S. drug company Merck & Co Inc said on Tuesday that its Chief Executive Ken Frazier plans to testify at a Senate hearing later this month examining rising prescription drug prices.

Select another date: